Trans American Aquaculture (GRPS) Cash & Equivalents (2023 - 2025)

Trans American Aquaculture (GRPS) reported Cash & Equivalents of $509.0 for Q3 2025, up 157.07% quarter-over-quarter from $198.0 in Q2 2025.

Trans American Aquaculture (GRPS) Cash & Equivalents (2023 - 2025) Analysis & Trends

Trans American Aquaculture has reported Cash & Equivalents for 2 years, with the latest figure at $509.0 in Q3 2025.

For the quarter ending Q3 2025, Cash & Equivalents changed N/A year-over-year to $509.0; the trailing twelve-month figure through Sep 2025 stood at $509.0 (changed N/A YoY), and the FY2023 full-year result was $6600.0, changed N/A from the prior year.
Cash & Equivalents for Q3 2025 stood at $509.0, up from $198.0 in the prior quarter.
The five-year high for Cash & Equivalents was $31480.0 in Q1 2023, with the low at $198.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	3.74 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	1.94 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	1.28 Bn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	40.42 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	266.50 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	428.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	351.55 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	222.27 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	498.58 Mn
10	Trans American Aquaculture	-	-	-	509.00

Download Data